Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04824794 · ClinicalTrials.gov registry record · Phase 1
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
A Phase 1 study, sponsored by Genmab.
- Terminated
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
NCT04824794 is a Phase 1 study that was terminated before completion, run by Genmab. The registered enrollment target is 130 participants.
The verdict
NCT04824794, a Phase 1 study, was terminated before completion, sponsored by Genmab.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
Study Summary
The drug that will be investigated in the study is an antibody, GEN3014. Since this is the first study of GEN3014 in humans, the main purpose is to evaluate safety. In addition to safety, the study will determine the recommended GEN3014 dose to be tested in a larger group of participants and assess preliminary clinical activity of GEN3014. GEN3014 will be studied in relapsed (disease has returned) or refractory (resistant to treatment) multiple myeloma (also known as RRMM) and other blood cancers. The study consists of 3 parts: 1. The Dose Escalation will test increasing doses of GEN3014 to identify a safe dose level to be tested in the other two parts. 2. Expansion Part A will further test the GEN3014 dose determined from the Dose Escalation. 3. Expansion Part B will compare intravenous (IV) GEN3014 with the subcutaneous (SC) daratumumab in ex-US countries. Participants will receive either GEN3014 into the vein or daratumumab under the skin; none will be given placebo. The study duration will be different for the individual participants. Overall, the study may be ongoing up to 5 years after the last participant's first treatment.
Interventions
- DRUG Daratumumab
- BIOLOGICAL GEN3014
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2021-03-09 |
| Est. Completion | 2025-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04824794
The ClinicalTrials.gov registry entry for NCT04824794 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genmab, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Daratumumab is the first listed.
NCT04824794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04824794 about?
NCT04824794 is a clinical study titled "GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies". The drug that will be investigated in the study is an antibody, GEN3014. Since this is the first study of GEN3014 in humans, the main purpose is to evaluate safety. In addition to safety, the study will determine the recommended GEN3014 dose to be tested in a larger group of participants and assess ...
What is the current status of trial NCT04824794?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2021-03-09. Estimated completion is 2025-07-31.
What interventions are being tested in trial NCT04824794?
The interventions under investigation include: Daratumumab (DRUG), GEN3014 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04824794?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.